Shots: 

• The CHMP’s positive opinion of mRESVIA to prevent lower respiratory tract disease (LTRD) due to RSV infection based on the P-III (ConquerRSV) study in adults (n=37,000; ≥60yrs.) 
• Primary analysis (3.7mos. median follow-up) showed vaccine efficacy (VE) of 83.7%, published in the NEJM. Supplementary analysis (8.6mos. median follow-up) showed sustained VE of 63.3% against RSV-LRTD incl. ≥2 symptoms with VE of 74.6% & 63% with ≥2 & ≥3 symptoms, respectively 
• In addition, the vaccine received the US FDA’s approval in May 2024 for the same. Furthermore, the company has filed MAA to other global authorities 

Ref:  Moderna | Image: Moderna

Related News:- Moderna Reports the P-III Study Data of mRNA-1283 Vaccine to Prevent COVID-19

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com